TW201726923A - 高純度半乳寡糖組合物及其製備方法與用途 - Google Patents
高純度半乳寡糖組合物及其製備方法與用途 Download PDFInfo
- Publication number
- TW201726923A TW201726923A TW106100460A TW106100460A TW201726923A TW 201726923 A TW201726923 A TW 201726923A TW 106100460 A TW106100460 A TW 106100460A TW 106100460 A TW106100460 A TW 106100460A TW 201726923 A TW201726923 A TW 201726923A
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- purity
- galactooligosaccharide
- galacto
- purity galactooligosaccharide
- Prior art date
Links
- 150000003271 galactooligosaccharides Chemical class 0.000 title claims abstract description 159
- 235000021255 galacto-oligosaccharides Nutrition 0.000 title claims abstract description 146
- 239000000203 mixture Substances 0.000 title claims abstract description 124
- 238000002360 preparation method Methods 0.000 title claims description 11
- 238000000855 fermentation Methods 0.000 claims abstract description 43
- 230000004151 fermentation Effects 0.000 claims abstract description 43
- 235000000346 sugar Nutrition 0.000 claims abstract description 39
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 28
- 150000002016 disaccharides Chemical class 0.000 claims abstract description 26
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 21
- 239000008280 blood Substances 0.000 claims abstract description 18
- 210000004369 blood Anatomy 0.000 claims abstract description 18
- FYGDTMLNYKFZSV-XJJKTWKOSA-N beta-(1->4)-galactotriose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H](CO)O[C@@H](O[C@H]2[C@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-XJJKTWKOSA-N 0.000 claims abstract description 16
- DBTMGCOVALSLOR-AXAHEAMVSA-N galactotriose Natural products OC[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](CO)O[C@@H](O[C@H]3[C@@H](O)[C@H](O)O[C@@H](CO)[C@@H]3O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O DBTMGCOVALSLOR-AXAHEAMVSA-N 0.000 claims abstract description 16
- 241001138401 Kluyveromyces lactis Species 0.000 claims abstract description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 10
- -1 galactotetrose Chemical class 0.000 claims abstract description 9
- 235000013402 health food Nutrition 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 6
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims description 31
- 230000000968 intestinal effect Effects 0.000 claims description 15
- 150000002972 pentoses Chemical class 0.000 claims description 15
- 229920001542 oligosaccharide Polymers 0.000 claims description 12
- 229930182830 galactose Natural products 0.000 claims description 10
- 241000235649 Kluyveromyces Species 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 150000002482 oligosaccharides Chemical class 0.000 claims description 5
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 1
- 150000002402 hexoses Chemical class 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 14
- 239000008103 glucose Substances 0.000 abstract description 14
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 201000010538 Lactose Intolerance Diseases 0.000 abstract description 4
- 230000006872 improvement Effects 0.000 abstract description 3
- 244000005709 gut microbiome Species 0.000 abstract description 2
- 235000013361 beverage Nutrition 0.000 abstract 1
- 239000000047 product Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 241000700159 Rattus Species 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 8
- 229940041514 candida albicans extract Drugs 0.000 description 8
- 239000012138 yeast extract Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000012295 chemical reaction liquid Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 150000004043 trisaccharides Chemical class 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000193468 Clostridium perfringens Species 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241000846455 Flavobacterium faecale Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003729 cation exchange resin Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000005417 food ingredient Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 235000000891 standard diet Nutrition 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 241000252867 Cupriavidus metallidurans Species 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000007413 intestinal health Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000010451 perlite Substances 0.000 description 2
- 235000019362 perlite Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000193752 Bacillus circulans Species 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960004642 ferric ammonium citrate Drugs 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 150000008195 galaktosides Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000004313 iron ammonium citrate Substances 0.000 description 1
- 235000000011 iron ammonium citrate Nutrition 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229960003548 polymyxin b sulfate Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本發明提供一種製備高純度半乳寡糖組合物的方法,係利用乳酸克魯維酵母菌ATCC 8585對一低純度半乳寡糖混合物進行發酵反應。該高純度半乳寡糖組合物包含至少99%選自於由半乳三糖、半乳四糖、五糖以上之半乳寡糖、及其任意組合所組成的群組,及低於1%之單糖及雙糖。本發明亦提供一種高純度半乳寡糖組合物,及其用於製備可調節血糖或改善腸道菌相之組合物之用途。例如,本發明高純度半乳寡糖組合物可用於製備適合糖尿病或乳糖不耐症病人或寵物使用之食品、飲品、保健食品、營養補充品、及醫藥組合物。
Description
本發明係關於一種半乳寡糖組合物及其製備方法與應用,特別係關於一種高純度半乳寡糖組合物及其製備方法,與其用於製備調節血糖與改善腸道菌相之組合物之用途。
半乳寡糖(galactooligosaccharides,GOS)屬於不可消化寡糖(non-digestible oligosaccharides,NDOs),是由二至十個半乳糖單元與一個末端葡萄糖單元所組成的寡糖分子,依其所含單糖單元個數,又分為半乳二糖、半乳三糖、半乳四糖、及五糖以上之半乳寡糖。市面上販售的半乳寡糖產品皆為上述不同分子量半乳寡糖之混合物,然其組成各異,且因為製程差異,尚包含含量不一的乳醣、蔗糖、葡萄糖、及半乳糖。半乳寡糖產品在產業上有相當廣泛的應用,包含食品添加物及醫藥組成物,其應用範圍取決於產品的糖分組成。例如,適合乳糖不耐症患者使用的半乳寡糖產品在理想情況下應完全不含乳糖,而以減低熱量為目標的半乳寡糖產品應儘量減少單糖含量。
目前已知製備半乳寡糖的方法大致分為酵素轉化或微生物發酵,然該些方法所製得的半乳寡糖粗產物皆含有殘留的單糖,如葡萄糖,以及雙糖,如乳糖。為因應市場需求,相關領域研究開始著重於改進半乳寡糖製程以降低產品中單糖及雙糖的含量。現行策略包括利用層析法(chromatography)或超濾(ultrafiltration)與奈米過濾(nanofiltration)等膜過濾法直接移除半乳寡糖粗產物中的單糖與雙糖,或者藉由酵素氧化法使單糖與雙糖氧化為糖酸,再以離子交換層析法移除該糖酸,抑或藉由微生物發酵消耗單糖與雙糖。然而,使用層析法或膜過濾法移除乳糖的效率不佳;使用酵素氧化法需耗費高成本,且難以
放大其規模至工業量產;微生物發酵則需要二種以上細菌或真菌菌株方能有效移除單糖與雙糖,增加製程上的複雜性。
因此,開發一種成本低廉、製程簡化、且可應用於工業量產高純度半乳寡糖組合物的方法,以提供一種不含單糖及雙糖的半乳寡糖組合物,實有其必要。
緣此,本發明之一目的在提供一種製備高純度半乳寡糖組合物的方法,包含如下步驟:(1)提供一反應液,係包含一低純度半乳寡糖混合物,以及(2)添加一乳酸克魯維酵母菌(Kluyveromyces lactis)至該反應液而進行一發酵反應,以獲得一高純度半乳寡糖組合物,其中該乳酸克魯維酵母菌係為乳酸克魯維酵母菌ATCC 8585,且該高純度半乳寡糖組合物包含至少99% w/w選自於由半乳三糖、半乳四糖、五糖以上之半乳寡糖、及其任意組合所組成的群組,及低於1% w/w之單糖及雙糖。
在本發明之一實施例中,該低純度半乳寡糖混合物之純度為55-60%;該反應液之白利(Brix)糖度為30-35;該乳酸克魯維酵母菌之添加量為該低純度半乳寡糖混合物乾重的至少約0.8%;該發酵反應係在30-40℃下持續24-72小時;且該高純度半乳寡糖組合物係為100%選自於由半乳三糖、半乳四糖、五糖以上之半乳寡糖、及其任意組合所組成的群組。
本發明之另一目的在提供一種高純度半乳寡糖組合物,包含至少99% w/w選自於由半乳三糖、半乳四糖、五糖以上之半乳寡糖、及其任意組合所組成的群組,且低於1% w/w之單糖及雙糖。
在本發明之一實施例中,該高純度半乳寡糖組合物係由一乳酸克魯維酵母菌(Kluyveromyces lactis)發酵製得,其中該乳酸克魯維酵母菌係為乳酸克魯維酵母菌ATCC 8585。同時,該高純度半乳寡糖組合物包含48-57% w/w之半乳三糖,25-32% w/w之半乳四糖,15-22% w/w之五糖以上之半乳寡糖。
本發明之又一目的在提供一種高純度半乳寡糖組合物用於製備一調節個體血糖之組合物之用途,其中該高純度半乳寡糖組合物包含至少99% w/w選自於由半乳三糖、半乳四糖、五糖以上之半乳寡糖、及其任意組合所組成的群組,及低於1% w/w之單糖及雙糖。
本發明之又一目的在提供一種高純度半乳寡糖組合物用於製備一改善個體腸道菌相之組合物之用途,其中該高純度半乳寡糖組合物包含至少99% w/w選自於由半乳三糖、半乳四糖、五糖以上之半乳寡糖、及其任意組合所組成的群組,及低於1% w/w之單糖及雙糖。
在本發明之一實施例中,該高純度半乳寡糖組合物包含48-57% w/w之半乳三糖,25-32% w/w之半乳四糖,及15-22% w/w之五糖以上之半乳寡糖,且其人體每日劑量為至少0.16g/kg體重,相當於60公斤成人每日至少攝取9.7克;該個體患有糖尿病;且該組合物為食品、飲品、保健食品、營養補充品、或醫藥組合物。
本發明製備高純度半乳寡糖組合物之方法係利用單一酵母菌株,即乳酸克魯維酵母菌ATCC 8585,進行發酵反應即製得純度99%以上之高純度半乳寡糖組合物,甚至製得純度100%之高純度半乳寡糖組合物。因此,本發明之方法係以相較於習知技術更加簡化的高純度半乳寡糖製程去製備不含單糖及雙糖的半乳寡糖產品,且能應用於大規模量產。本發明高純度半乳寡糖組合物因其組成,能有效降低糖尿病患者的血糖,亦能改善腸道菌相而維持腸道健康,因此可用於製備調節血糖或改善腸道菌相之組合物。例如,本發明高純度半乳寡糖組合物可用於製備適合糖尿病或乳糖不耐症病人或寵物使用之食品、飲品、保健食品、營養補充品、及醫藥組合物。
以下將配合圖式進一步說明本發明的實施方式,下述所列舉的實施例係用以闡明本發明之發明特點及應用,而非以限定本發明之範圍,任何熟習此技藝者,在不脫離本發明之精神和範圍內,當可做些許更動與潤飾,因此本發明之保護範圍當視後附之申請專利範圍所界定者為準。
圖1係顯示本發明純度100%之高純度半乳寡糖組合物降低糖尿病大鼠之空腹血糖上升率。
圖2係顯示本發明純度100%之高純度半乳寡糖組合物促進糖尿病大鼠之腸道益生菌生長及抑制有害菌生長;*表示p<0.1,**表示p<0.05。
本文中所使用數值為近似值,所有實驗數據皆在20%的範圍內變動,較佳為在10%的範圍內,最佳為在5%的範圍內。因此,本文中用語「約」係表示一數值或範圍之20%的範圍內,較佳為在10%的範圍內,最佳為在5%的範圍內。
本文中所述「有效劑量」係用以表示能降低動物及人類空腹葡萄糖值或改善其腸道菌相之高純度半乳寡糖組合物劑量。適當的有效劑量依施予生物體或個體的不同而有所差異,但可以包含劑量遞增之研究方式的各種實驗技術決定有效劑量。
本文中所謂半乳寡糖的「純度」,係依據高效液相層析(high performance liquid chromatography,以下簡稱HPLC)的圖譜中,半乳三糖、半乳四糖、及五糖以上半乳寡糖之訊號加總相對於總糖訊號的面積比。
本發明提供一種製備高純度半乳寡糖組合物及其製備方法。進行製備時,以純度為約55-60%的低純度半乳寡糖混合物為原料,經蒸餾水稀釋為白利(Brix)糖度約30-35之反應液後,添加1%酵母菌萃取物及0.3-0.8%乳酸克魯維酵母菌ATCC 8585至該反應液,於30-40℃下進行發酵反應24-72小時。在本發明一實施例中,該發酵反應係於30噸發酵槽中以20噸發酵液進行,通氣量3-5L/min,轉速150rpm,發酵pH值為5.0-5.6。當發酵液中單糖與雙糖含量達到1% w/w以下且半乳寡糖產物之純度已達至少99%,加熱發酵液至90-95℃終止發酵反應,便可獲得本發明高純度半乳寡糖組合物的初產品。
其後,為去除雜質以獲得可供食用之高純度半乳寡糖組合物,以離心方式沉澱發酵液中酵母菌及酵母萃取物並利用珍珠岩過濾器(Perlite filter)移除該沉澱。在本發明一實施例中,該離心步驟係在6-10℃下以15000rpm進行5-10小時。其後,發酵液進一步經過活性碳脫色去除色素,再經過陽離子交換樹脂及陰離子交換樹脂去除其中礦物質,最後以蒸汽濃縮法去除水分,即可獲得本發明高純度半乳寡糖組合物的終產品。其糖分組成為單糖及雙糖占比低於1% w/w、半乳三糖約占48-57% w/w、半乳四糖約占25-32% w/w、及五糖以之上半乳寡糖約占15-22% w/w。
乳酸克魯維酵母菌ATCC 8585(BCRC 21716)由生物資源保存及研究中心(新竹市)購得。酵母萃取物可由安琪酵母公司(中國)購得,但不在此限。磺化苯乙烯-二乙烯基苯共聚物(sulfonated styrene-divinylbenzene copolymer)之陽離子交換樹脂以及帶有三級胺基團之苯乙烯-二乙烯基苯共聚物(styrene-divinylbenzene copolymer with tertiary amine groups)之陰離子交換樹脂由Sigma-Aldrich公司(美國)購得。
本發明用於製備高純度半乳寡糖組合物之低純度半乳寡糖混合物原料,可直接向雲浮市新金山生物科技股份有限公司(中國)購買,或可由環狀芽孢桿菌(Bacillus circulans)的β-半乳糖苷酶(β-galactosidase)轉化乳糖所製備,該低純度半乳寡糖混合物的純度為約55-60%,以57%為最佳。乳糖轉化係在30-50℃下進行48-72小時,乳糖初始濃度為40-60%(w/w)。
發酵液之糖分組成分析係利用高效液相層析儀裝配鈣型陽離子交換管柱(CARBOSep CHO-620,Transgennomic公司,美國)。將發酵液樣品加水稀釋至2%,並以折射率偵測器(refractive index detector)偵測沖提液中糖類之訊號,紀錄分離出的各種糖類的波峰滯留時間及訊號強度。對照糖類標準品的訊號做成定性分析,並以層析圖譜中各種糖類訊號的波鋒面積計算各種糖類在總糖中的占比。
將約1g大鼠盲腸內容物加入含9mL無菌厭氧稀釋液(0.5g半胱胺酸,4.5g磷酸二氫鉀,6g磷酸氫二鈉,1g聚山梨醇酯20,2g明膠,溶於1L去離子水)與5粒玻璃珠之試管中,以試管震盪器混合二者以形成均質液。於厭氧狀況下,以厭氧稀釋液對該均質液進行十倍連續稀釋。將適當稀釋倍數之均質液0.1mL塗布於比菲德氏菌(Bifidobacterium)BIM-25培養基(51g強化梭菌洋菜培養基,0.02g耐啶酸,0.0085g硫酸多黏菌素B,0.05g硫酸卡納黴素,0.0025g碘乙酸,0.025g氯化三苯四氮唑,溶於1L去離子水)或乳酸桿菌(Lactobacillus)選擇性MRS培養基(55g乳酸桿菌MRS肉湯(Difco),20g洋菜,1.2mL醋酸,3g苯乙醇,0.04g溴甲酚綠,溶於1L去離子水),置於厭氧操作箱中於37℃培養16小時,計算比菲德氏菌或乳酸桿菌的菌落數。產氣莢膜梭菌(Clostridium)之計數,係將
適當稀釋倍數之上述均質液0.1mL塗布於添加蛋黃液之TSC培養基(15g胰蛋白腖,5g酵母萃取物,5g大豆蛋白腖,1g檸檬酸鐵銨,1g偏亞硫酸鈉,20g洋菜,溶於1L去離子水),待乾燥後,再倒入約5-10mL不含蛋黃液之TSC培養基,置於厭氧操作箱中於37℃培養24小時,計算產氣莢膜梭的菌落數。腸道菌數依下列公式計算:
為評估反應液糖度對半乳寡糖產物純度的影響,將純度57%的低純度半乳寡糖混合物以蒸餾水稀釋為白利糖度30、35、或40的反應液,分別命名為A、B、C三組,並調整反應液pH值至5.0-5.6。其次,加入重量比1%的酵母萃取物(以低純度半乳寡糖混合物乾重為基準)並加熱至其溶解,使反應液降溫至30-40℃,再加入重量比0.5%的乳酸克魯維酵母菌ATCC 8585(以低純度半乳寡糖混合物乾重為基準)。通氣攪拌發酵24小時及48小時,自發酵液取樣以HPLC進行成分分析。
不同糖度反應液之發酵結果如表1所示。經成分分析,A、B、C三組在持續發酵24小時後,其三糖以上之半乳寡糖占發酵液總糖之比例分別為79.3% w/w、82.6% w/w、及67.9% w/w。在持續發酵48小時後,A、B、C三組的三糖以上之半乳寡糖占發酵液總糖之比例分別增加為92.3% w/w、95.4% w/w、及80.5% w/w。此結果顯示乳酸克魯維酵母菌ATCC 8585於反應液之白利糖度為35時具有最佳的單糖及雙糖消耗能力。
為評估酵母菌添加量對半乳寡糖產物純度的影響,將純度57%的低純度半乳寡糖混合物以蒸餾水稀釋為白利糖度35的反應液,並調整反應液pH值至5.0-5.6。其次,加入重量比1%的酵母萃取物(以低純度半乳寡糖混合物乾重為基準)並加熱至其溶解,使反應液降溫至30-40℃,再加入重量比0.3%、0.5%、或0.8%的乳酸克魯維酵母菌ATCC 8585(以低純度半乳寡糖混合物乾重為基準),所得三種反應液分別命名為D、E、F三組。通氣攪拌發酵24小時及48小時,自發酵液取樣以HPLC進行成分分析。
不同酵母菌添加量之反應液之發酵結果如表2所示。經成分分析,D、E、F三組在持續發酵24小時後,其三糖以上之半乳寡糖占發酵液總糖之比例分別為76.4% w/w、82.0% w/w、及90.2% w/w。在持續發酵48小時後,D、E、F三組的三糖以上之半乳寡糖占發酵液總糖之比例分別增加為87.8% w/w、95.7% w/w、及100% w/w。此結果顯示當乳酸克魯維酵母菌ATCC 8585的添加量為0.5%,可獲得純度95%以上之三糖以上之半乳寡糖產物;當該菌的添加量為0.8%,可獲得純度高達100%之三糖以上之半乳寡糖產物。
依據上述實施例1-2,將單一菌株之乳酸克魯維酵母菌ATCC 8585加入低純度半乳寡糖進行發酵反應,可使發酵液中的單糖及雙糖被完全消耗,因此獲得不含單糖及雙糖的本發明高純度半乳寡糖組合物的初產品。
為進行更精確的分析,本實施例先移除前述高純度半乳寡糖組合物的初產品中的不可食用雜質及水分,再以HPLC測定本發明高純度半乳寡糖組合物的糖分組成。首先,將純度57%的低純度半乳寡糖混合物以蒸餾水稀釋為白利糖度35的反應液,並調整反應液pH值至5.0-5.6。其次,加入重量比1%的酵母萃取物(以低純度半乳寡糖混合物乾重為基準)並加熱至其溶解,使反應液降溫至30-40℃,再加入重量比0.8%的乳酸克魯維酵母菌ATCC 8585(以低純度半乳寡糖混合物乾重為基準)。通氣攪拌發酵48-72小時,當發酵液中三糖以上之半乳寡糖占總糖之比例達100%時,加熱至90-95℃終止發酵反應。將此高純度半乳寡糖發酵液經過離心沉澱其中酵母菌及酵母萃取物,以珍珠岩過濾器移除該沉澱,再經活性碳脫色去除發酵過程產生的色素,並經陽離子交換樹脂與陰離子交換樹脂去除礦物質,最終以蒸氣濃縮得到高純度半乳寡糖糖漿,再經乾燥即可得到高純度半乳寡糖糖粉。
表3顯示三批次所得高純度半乳寡糖糖粉之糖分組成。綜合而言,本發明高純度半乳寡糖組合物包含1% w/w以下單糖及雙糖,較佳為不含單糖及雙糖,約48-57% w/w半乳三糖,約25-32% w/w半乳四糖,以及約15-22% w/w五糖以上之半乳寡糖。
本實施例以誘發糖尿病的Sprague Dawley大鼠(簡稱SD大鼠)為模型,比較本發明純度100%之高純度半乳寡糖組合物相對於純度95%之半乳寡糖組合物的降血糖效果。首先,將經過2週適應期的40隻SD大鼠依每組10隻隨機分配為四組,分別為健康組、糖尿病組、100% GOS組、及95% GOS組,適應期間餵食標準飼糧(AIN-93)。除了健康組,其他三組皆以腹腔注射鏈佐黴素(streptozotocin,STZ)65mg/kg及菸鹼醯胺(nicotinamide)230mg/kg以誘發糖尿
病,至該三組大鼠的空腹血糖值達糖尿病標準之230±10mg/dL以上。其後,健康組與糖尿病組繼續餵食標準飼糧,95% GOS組及100% GOS組則以管灌方式分別餵食溶於生理食鹽水的純度95%之半乳寡糖組合物與本發明純度100%之高純度半乳寡糖組合物。該二種半乳寡糖組合物的給予劑量各為1g/kg體重/天。本實施例所使用純度95%之半乳寡糖組合物與本發明純度100%之高純度半乳寡糖組合物,其糖分組成如表4所示。經過2週餵食,利用六碳糖激醃法(hexokinase assay)的商業套組(Quick Auto Neo GLU-HK)配合生化分析儀(HITACHI 7080,Japan),測定大鼠於餵食前後的空腹血糖值(禁食24小時之血糖值)並計算其值變化。
大鼠的空腹血糖值變化與空腹血糖上升率分別如表5與圖1所示。相對於健康組,糖尿病組的空腹血糖值明顯增加。然而,95% GOS組與100% GOS組的空腹血糖值相對於半乳寡糖餵食前顯著下降,且以100% GOS組的空腹血糖值下降最多,達到25%。此結果顯示本發明高純度半乳寡糖組合物因為降低單糖及雙糖含量,以及增加半乳三糖及半乳四糖占比,具有大幅降低血糖的功效。本實施例中施用於大鼠的本發明高純度半乳寡糖組合物的劑量為1g/kg體重/天,按照2005年美國食品藥物管理局所公告之實驗初期估算方法換算,其用於人類個體的每日劑量為約0.16g/kg體重。
本實施例以誘發糖尿病的SD大鼠為模型,比較本發明純度100%之高純度半乳寡糖組合物相對於純度95%之半乳寡糖組合物,在改善個體腸道菌相的效果。類同實施例4之說明,將40隻SD大鼠依每組10隻隨機分配為四組,分別為健康組、糖尿病組、95% GOS組、及100% GOS組。經過誘發糖尿病處理後,健康組與糖尿病組餵食標準飼糧,95% GOS組及100% GOS組則以管灌方式分別餵食溶於生理食鹽水的純度95%之半乳寡糖組合物與本發明純度100%之高純度半乳寡糖組合物。該二種半乳寡糖組合物的給予劑量各為1g/kg體重/天。本實施例所用純度95%之半乳寡糖組合物與本發明純度100%之高純度半乳寡糖組合物,其糖分組成如表4所示。經過2週餵食,分析大鼠於餵食前後的腸道菌相。
圖2顯示益生菌,如乳酸桿菌及比菲德氏菌,與有害菌,如產氣莢膜梭菌,在大鼠腸道之估計菌數。相對於糖尿病組,100% GOS組的腸道內比菲德氏菌數量明顯增加,但產氣莢膜梭菌數量減少。相對而言,在95% GOS組並未觀察到腸道內比菲德氏菌數量增加,但卻有較多的產氣莢膜梭菌生長。此結果顯示本發明高純度半乳寡糖組合物能有效促進腸道益生菌生長,並因此抑制有害菌生長,導致有效改善腸道菌相。本實施例中施用於大鼠的本發明高純度半乳寡糖組合物的劑量為1g/kg體重/天,按照2005年美國食品藥物管理局所公告之實驗初期估算方法換算,其用於人類個體的每日劑量為約0.16g/kg體重。
綜上所述,本發明製備高純度半乳寡糖組合物之方法係利用單一酵母菌株,即乳酸克魯維酵母菌ATCC 8585,進行發酵反應即製得純度99%以上之高純度半乳寡糖組合物,其包含至少99% w/w選自於由半乳三糖、半乳四糖、五糖以上之半乳寡糖、及其任意組合所組成的群組,及低於1% w/w之單糖及雙糖,最佳為100%選自於由半乳三糖、半乳四糖、五糖以上之半乳寡糖、及其任意組合所組成的群組。本發明高純度半乳寡糖組合物較純度95%之半乳寡糖組合物更有效降低糖尿病患者的血糖,亦能顯著改善腸道菌相而維持腸道健康,因此可用於製備調節血糖或改善腸道菌相之組合物。例如,本發明高純度半乳寡糖組合物可用於製備適合糖尿病或乳糖不耐症病人或寵物使用之食品、飲品、保健食品、營養補充品、及醫藥組合物等產品,該些產品可為粉末、液體、或即可使用(ready-to-use),且該些產品可以進一步包含選自由一食材成分及一保健
食品成分所組成的群組。前述食材成份可為蔬果或肉類等,前述保健食品成份可為牛磺酸、維生素、菸鹼酸或其他有益健康之成分,但不在此限。
Claims (19)
- 一種製備高純度半乳寡糖組合物的方法,包含如下步驟:(1)提供一反應液,係包含一低純度半乳寡糖混合物;以及(2)添加一乳酸克魯維酵母菌(Kluyveromyces lactis)至該反應液而進行一發酵反應,以獲得一高純度半乳寡糖組合物;其中該乳酸克魯維酵母菌係為乳酸克魯維酵母菌ATCC 8585,且該高純度半乳寡糖組合物包含至少99% w/w選自於由半乳三糖、半乳四糖、五糖以上之半乳寡糖、及其任意組合所組成的群組,及低於1% w/w之單糖及雙糖。
- 如申請專利範圍第1項所述之方法,其中該低純度半乳寡糖混合物之純度為55-60%。
- 如申請專利範圍第1項所述之方法,其中該反應液之白利(Brix)糖度為30-35。
- 如申請專利範圍第1項所述之方法,其中該乳酸克魯維酵母菌之添加量為該低純度半乳寡糖混合物乾重的至少約0.8%。
- 如申請專利範圍第1項所述之方法,其中該發酵反應係在30-40℃下持續24-72小時。
- 如申請專利範圍第1項所述之方法,其中該高純度半乳寡糖組合物係為100%選自於由半乳三糖、半乳四糖、五糖以上之半乳寡糖、及其任意組合所組成的群組。
- 一種高純度半乳寡糖組合物,包含至少99% w/w選自於由半乳三糖、半乳四糖、五糖以上之半乳寡糖、及其任意組合所組成的群組,及低於1% w/w之單糖及雙糖。
- 如申請專利範圍第7項所述之高純度半乳寡糖組合物,其係包含48-57% w/w之半乳三糖,25-32% w/w之半乳四糖,及15-22% w/w之五糖以上之半乳寡糖。
- 如申請專利範圍第7項所述之高純度半乳寡糖組合物,其係由一乳酸克魯維酵母菌(Kluyveromyces lactis)發酵製得,其中該乳酸克魯維酵母菌係為乳酸克魯維酵母菌ATCC 8585。
- 一種高純度半乳寡糖組合物用於製備一調節個體血糖之組合物之用途,其中該高純度半乳寡糖組合物包含至少99% w/w選自於由半乳三糖、半乳四糖、五糖以上之半乳寡糖、及其任意組合所組成的群組,及低於1% w/w之單糖及雙糖。
- 如申請專利範圍第10項所述之用途,其中該高純度半乳寡糖組合物包含48-57% w/w之半乳三糖,25-32% w/w之半乳四糖,及15-22% w/w之五糖以上之半乳寡糖。
- 如申請專利範圍第10項所述之用途,其中該高純度半乳寡糖組合物之人體每日劑量為至少0.16g/kg體重。
- 如申請專利範圍第10項所述之用途,其中該個體患有糖尿病。
- 如申請專利範圍第10項所述之用途,其中該組合物係為食品、飲品、保健食品、營養補充品、或醫藥組合物。
- 一種高純度半乳寡糖組合物用於製備一改善個體腸道菌相之組合物之用途,其中該高純度半乳寡糖組合物包含至少99% w/w選自於由半乳三糖、半乳四糖、五糖以上之半乳寡糖、及其任意組合所組成的群組,及低於1% w/w之單糖及雙糖。
- 如申請專利範圍第15項所述之用途,其中該高純度半乳寡糖組合物包含48-57% w/w之半乳三糖,25-32% w/w之半乳四糖,及15-22% w/w之五糖以上之半乳寡糖。
- 如申請專利範圍第15項所述之用途,其中該高純度半乳寡糖組合物之人體每日劑量為至少0.16g/kg體重。
- 如申請專利範圍第15項所述之用途,其中該個體患有糖尿病。
- 如申請專利範圍第15項所述之用途,其中該組合物係為食品、飲品、保健食品、營養補充品、或醫藥組合物。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662286808P | 2016-01-25 | 2016-01-25 | |
US62/286,808 | 2016-01-25 | ||
US15/399,545 US10190142B2 (en) | 2016-01-25 | 2017-01-05 | High-purity galactooligosaccharide compositions, preparations, and applications thereof |
US15/399,545 | 2017-01-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201726923A true TW201726923A (zh) | 2017-08-01 |
TWI645041B TWI645041B (zh) | 2018-12-21 |
Family
ID=57799545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW106100460A TWI645041B (zh) | 2016-01-25 | 2017-01-06 | 高純度半乳寡糖組合物及其製備方法與用途 |
Country Status (4)
Country | Link |
---|---|
US (3) | US10190142B2 (zh) |
EP (1) | EP3205727A3 (zh) |
CN (1) | CN106994130B (zh) |
TW (1) | TWI645041B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111334541A (zh) * | 2020-02-24 | 2020-06-26 | 天津大学 | 一种β-半乳糖苷酶制备高纯度低聚半乳糖的方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111165825A (zh) * | 2019-07-17 | 2020-05-19 | 江苏西宏生物医药有限公司 | 一种术前经肠营养组合物 |
BR112022010040A2 (pt) * | 2019-11-27 | 2022-08-16 | Glycom As | Mistura de hmos |
WO2023161321A1 (en) | 2022-02-25 | 2023-08-31 | Frieslandcampina Nederland B.V. | Process for preparing high purity galacto-oligosaccharide |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2284028T5 (es) | 2003-06-30 | 2014-12-04 | Clasado Inc. | Nueva composición de galactooligosacárido y la preparación de la misma |
WO2008054193A1 (en) * | 2006-11-02 | 2008-05-08 | N.V. Nutricia | Nutritional products that comprise saccharide oligomers |
WO2009113030A2 (en) | 2008-03-12 | 2009-09-17 | Tata Chemicals Ltd. | Process for the production of galactooligosaccharides by free cells |
KR20110124780A (ko) * | 2009-02-24 | 2011-11-17 | 리터 파마슈티컬즈 인코오포레이티드 | 프리바이오틱 제제 및 사용 방법 |
IT1395068B1 (it) | 2009-08-07 | 2012-09-05 | Inalco Spa | Processo per la produzione di galatto-oligosaccaridi ultrapuri |
WO2011093907A1 (en) | 2010-02-01 | 2011-08-04 | Corn Products International, Inc. | High-purity galactooligosaccharides and uses thereof |
WO2011137249A1 (en) * | 2010-04-28 | 2011-11-03 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
WO2015175412A1 (en) | 2014-05-12 | 2015-11-19 | Ritter Pharmaceuticals, Inc. | Methods and systems for galactooligosac-charides manufacture |
-
2017
- 2017-01-05 US US15/399,545 patent/US10190142B2/en active Active
- 2017-01-06 CN CN201710010713.XA patent/CN106994130B/zh active Active
- 2017-01-06 TW TW106100460A patent/TWI645041B/zh active
- 2017-01-09 EP EP17150672.8A patent/EP3205727A3/en active Pending
-
2018
- 2018-02-22 US US15/902,499 patent/US10612060B2/en active Active
- 2018-02-22 US US15/902,409 patent/US10385373B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111334541A (zh) * | 2020-02-24 | 2020-06-26 | 天津大学 | 一种β-半乳糖苷酶制备高纯度低聚半乳糖的方法 |
Also Published As
Publication number | Publication date |
---|---|
US10612060B2 (en) | 2020-04-07 |
US20170211112A1 (en) | 2017-07-27 |
US20180179566A1 (en) | 2018-06-28 |
TWI645041B (zh) | 2018-12-21 |
EP3205727A2 (en) | 2017-08-16 |
US10385373B2 (en) | 2019-08-20 |
US10190142B2 (en) | 2019-01-29 |
CN106994130A (zh) | 2017-08-01 |
US20180179567A1 (en) | 2018-06-28 |
CN106994130B (zh) | 2020-06-19 |
EP3205727A3 (en) | 2017-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Panesar et al. | Lactulose: production, purification and potential applications | |
Hernández et al. | Comparison of fractionation techniques to obtain prebiotic galactooligosaccharides | |
Seki et al. | Lactose as a source for lactulose and other functional lactose derivatives | |
TWI645041B (zh) | 高純度半乳寡糖組合物及其製備方法與用途 | |
CN102271535B (zh) | 生产唾液酸的细菌 | |
Cardelle-Cobas et al. | Bifidogenic effect and stimulation of short chain fatty acid production in human faecal slurry cultures by oligosaccharides derived from lactose and lactulose | |
CN106387572A (zh) | 一种枸杞益生菌饮料及其制备方法 | |
CN112244101B (zh) | 一种充气活菌透明乳清饮料及其制备方法 | |
US20230404094A1 (en) | Fermented milk for regulating gut health and preparation method thereof | |
WO2023170426A1 (en) | Galactooligosaccharide composition | |
CN104222281A (zh) | 一种功能性复合益生元及其乳制品 | |
CN108402454B (zh) | 红心火龙果酵素、制备方法及其应用 | |
CN107712047B (zh) | 一种复合乳酸菌发酵风味的原味乳酸菌饮料及其制备方法 | |
Aidarbekova et al. | Study of the physico-chemical, structural, microbiological properties and volatile flavour compounds profile of kefir supplemented with electro-activated whey | |
CN113951409B (zh) | 一种活菌型不老莓发酵果汁及其加工方法 | |
CN107372826A (zh) | 一种无糖酸奶及其制备方法 | |
KR20140147934A (ko) | 유청과 표고버섯 자실체 추출물의 혼합 발효를 통한 기능성 음료의 제조방법 | |
Kaewsedam et al. | Modulation of gut microbiota and their metabolites by functional mulberry juice non-thermally pasteurized using microfiltration | |
CN109943494B (zh) | 培养基及其制备方法 | |
KR101783673B1 (ko) | 유아 분변에서 분리한 균주 및 이를 이용한 항산화 기능을 갖는 발효유의 제조방법 | |
EP2525674B1 (en) | Prebiotic use of water soluble soybean polysaccharide | |
Jung et al. | Production and application of galacto-oligosaccharides from lactose by a recombinant β-galactosidase of Bifidobacterium infantis overproduced by Pichia pastoris | |
JP2018523634A (ja) | プレバイオティクス飲料に含まれるアガベフルクタンの濃縮方法および過程 | |
TWI730719B (zh) | 植物醱酵物及其製造方法、含彼之組成物暨其用途 | |
JP7462618B2 (ja) | タガトース及びガラクトースシロップ |